CL2017003320A1 - Formulaciones farmacéuticas que contienen tenofovir y emtricitabina - Google Patents
Formulaciones farmacéuticas que contienen tenofovir y emtricitabinaInfo
- Publication number
- CL2017003320A1 CL2017003320A1 CL2017003320A CL2017003320A CL2017003320A1 CL 2017003320 A1 CL2017003320 A1 CL 2017003320A1 CL 2017003320 A CL2017003320 A CL 2017003320A CL 2017003320 A CL2017003320 A CL 2017003320A CL 2017003320 A1 CL2017003320 A1 CL 2017003320A1
- Authority
- CL
- Chile
- Prior art keywords
- emtricitabine
- pharmaceutical formulations
- formulations containing
- acceptable salt
- same
- Prior art date
Links
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 title abstract 3
- 229960000366 emtricitabine Drugs 0.000 title abstract 3
- 229960004556 tenofovir Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000006186 oral dosage form Substances 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- SGOIRFVFHAKUTI-ZCFIWIBFSA-N tenofovir (anhydrous) Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 abstract 1
- LDEKQSIMHVQZJK-CAQYMETFSA-N tenofovir alafenamide Chemical compound O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 LDEKQSIMHVQZJK-CAQYMETFSA-N 0.000 abstract 1
- 229960004946 tenofovir alafenamide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
<p>LA INVENCIÓN PROPORCIONA UNA FORMA DE DOSIFICACIÓN ORAL SÓLIDA QUE COMPRENDE ALAFENAMIDA DE TENOFOVIR O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LA MISMA, Y EMTRICITABINA O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LA MISMA. LA INVENCIÓN PROPORCIONA UNA FORMA DE DOSIFICACIÓN ORAL SÓLIDA QUE COMPRENDE ALAFENAMIDA DE TENOFOVIR O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LA MISMA, Y EMTRICITABINA O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LA MISMA.</p>
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187113P | 2015-06-30 | 2015-06-30 | |
| US201662298373P | 2016-02-22 | 2016-02-22 | |
| US201662301429P | 2016-02-29 | 2016-02-29 | |
| US201662317286P | 2016-04-01 | 2016-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017003320A1 true CL2017003320A1 (es) | 2018-07-13 |
Family
ID=56418608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017003320A CL2017003320A1 (es) | 2015-06-30 | 2017-12-21 | Formulaciones farmacéuticas que contienen tenofovir y emtricitabina |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20170000807A1 (es) |
| EP (5) | EP4070787B1 (es) |
| JP (3) | JP6667556B2 (es) |
| KR (2) | KR102313668B1 (es) |
| CN (1) | CN107847450A (es) |
| AU (3) | AU2016287500B2 (es) |
| BR (1) | BR112017027843A2 (es) |
| CA (1) | CA2990210C (es) |
| CL (1) | CL2017003320A1 (es) |
| CO (1) | CO2017013293A2 (es) |
| CU (1) | CU20170168A7 (es) |
| DO (1) | DOP2017000306A (es) |
| EA (1) | EA201792592A1 (es) |
| EC (1) | ECSP17084331A (es) |
| ES (4) | ES2925246T3 (es) |
| HK (1) | HK1248547A1 (es) |
| IL (1) | IL256364A (es) |
| MA (1) | MA50541A (es) |
| MX (1) | MX2017016806A (es) |
| PE (1) | PE20180411A1 (es) |
| PH (1) | PH12017502431A1 (es) |
| PL (4) | PL4070787T3 (es) |
| PT (4) | PT3607939T (es) |
| SI (4) | SI3607939T1 (es) |
| SV (1) | SV2017005601A (es) |
| WO (1) | WO2017004244A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3067358T3 (da) | 2012-12-21 | 2019-11-04 | Gilead Sciences Inc | Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse |
| KR20170123308A (ko) | 2014-12-26 | 2017-11-07 | 에모리 유니버시티 | Ｎ4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도 |
| CN113546052A (zh) | 2015-11-09 | 2021-10-26 | 吉利德科学公司 | 治疗人免疫缺陷病毒的治疗组合物 |
| MA47511A (fr) | 2017-02-17 | 2019-12-25 | Eidos Therapeutics Inc | Procédés de préparation d'ag-10, de ses intermédiaires et de sels correspondants |
| WO2018153977A1 (en) * | 2017-02-24 | 2018-08-30 | Hexal Ag | Stable composition of tenofovir alafenamide |
| AU2018239257B2 (en) * | 2017-03-20 | 2023-09-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV post-exposure prophylaxis |
| RU2662160C9 (ru) | 2017-07-03 | 2018-10-22 | Александрович Иващенко Андрей | Комбинированный лекарственный препарат для терапии вирусных инфекций |
| BR122022008466B1 (pt) | 2017-12-07 | 2023-12-05 | Emory University | Uso de um composto |
| WO2020037189A1 (en) * | 2018-08-17 | 2020-02-20 | Eidos Therapeutics, Inc. | Formulations of ag10 |
| CN111096954B (zh) * | 2018-10-29 | 2022-09-16 | 江苏豪森药业集团有限公司 | 一种用于抗病毒感染的药物组合物及制备方法 |
| CN110251476B (zh) * | 2019-08-01 | 2022-08-09 | 海思科制药(眉山)有限公司 | 一种恩曲他滨替诺福韦药物组合物 |
| CN110917197A (zh) * | 2019-12-31 | 2020-03-27 | 常州恒邦药业有限公司 | 一种替诺福韦酯与恩曲他滨的药物组合物及其制备方法 |
| TWI728709B (zh) * | 2020-02-19 | 2021-05-21 | 台灣森本生物科技開發股份有限公司 | 含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方 |
| CN117338733B (zh) * | 2023-10-12 | 2024-05-28 | 杭州和泽坤元药业有限公司 | 一种富马酸替诺福韦二吡呋酯片及其制备工艺 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100767432B1 (ko) | 2000-07-21 | 2007-10-17 | 길리애드 사이언시즈, 인코포레이티드 | 포스포네이트 뉴클레오티드 유사체의 전구 약물과 그것의 선택 및 제조 방법 |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| DE602004014470D1 (de) * | 2003-01-14 | 2008-07-31 | Gilead Sciences Inc | Zusammensetzungen und verfahren zur antiviralen kombinationstherapie |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| MX2011008289A (es) | 2009-02-06 | 2011-09-15 | Gilead Sciences Inc | Tabletas para terapia combinada. |
| RS55353B2 (sr) | 2011-08-16 | 2023-11-30 | Gilead Sciences Inc | Tenofovir alafenamid hemifumarat |
| EA026138B1 (ru) * | 2012-02-03 | 2017-03-31 | Джилид Сайэнс, Инк. | Комбинированная терапия, включающая тенофовир алафенамида гемифумарат и кобицистат, для применения для лечения вирусных инфекций |
| JP2016528240A (ja) * | 2013-08-14 | 2016-09-15 | ラシオファルム ゲーエムベーハー | ドルテグラビル、エムトリシタビン及びテノホビルの医薬コンビネーションを有する医薬 |
| CZ2013985A3 (cs) * | 2013-12-09 | 2015-06-17 | Zentiva, K.S. | Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát |
| NO2717902T3 (es) * | 2014-06-20 | 2018-06-23 |
-
2016
- 2016-06-29 PT PT191992577T patent/PT3607939T/pt unknown
- 2016-06-29 SI SI201631582T patent/SI3607939T1/sl unknown
- 2016-06-29 SI SI201630656T patent/SI3316868T1/sl unknown
- 2016-06-29 MX MX2017016806A patent/MX2017016806A/es unknown
- 2016-06-29 KR KR1020207016036A patent/KR102313668B1/ko active IP Right Grant
- 2016-06-29 MA MA050541A patent/MA50541A/fr unknown
- 2016-06-29 BR BR112017027843-0A patent/BR112017027843A2/pt not_active Application Discontinuation
- 2016-06-29 EP EP22176524.1A patent/EP4070787B1/en active Active
- 2016-06-29 EP EP16739625.8A patent/EP3316868B1/en active Active
- 2016-06-29 EA EA201792592A patent/EA201792592A1/ru unknown
- 2016-06-29 SI SI201631702T patent/SI4070788T1/sl unknown
- 2016-06-29 WO PCT/US2016/040158 patent/WO2017004244A1/en active Application Filing
- 2016-06-29 PL PL22176524.1T patent/PL4070787T3/pl unknown
- 2016-06-29 PL PL19199257.7T patent/PL3607939T3/pl unknown
- 2016-06-29 SI SI201631707T patent/SI4070787T1/sl unknown
- 2016-06-29 PT PT167396258T patent/PT3316868T/pt unknown
- 2016-06-29 CU CUP2017000168A patent/CU20170168A7/es unknown
- 2016-06-29 CA CA2990210A patent/CA2990210C/en active Active
- 2016-06-29 PL PL16739625T patent/PL3316868T3/pl unknown
- 2016-06-29 PL PL22176537.3T patent/PL4070788T3/pl unknown
- 2016-06-29 ES ES19199257T patent/ES2925246T3/es active Active
- 2016-06-29 EP EP23162978.3A patent/EP4233846A3/en active Pending
- 2016-06-29 PT PT221765373T patent/PT4070788T/pt unknown
- 2016-06-29 AU AU2016287500A patent/AU2016287500B2/en active Active
- 2016-06-29 ES ES22176524T patent/ES2945345T3/es active Active
- 2016-06-29 KR KR1020187002382A patent/KR102121329B1/ko active IP Right Grant
- 2016-06-29 EP EP19199257.7A patent/EP3607939B1/en active Active
- 2016-06-29 CN CN201680045136.1A patent/CN107847450A/zh active Pending
- 2016-06-29 US US15/197,491 patent/US20170000807A1/en not_active Abandoned
- 2016-06-29 EP EP22176537.3A patent/EP4070788B1/en active Active
- 2016-06-29 PT PT221765241T patent/PT4070787T/pt unknown
- 2016-06-29 ES ES22176537T patent/ES2945896T3/es active Active
- 2016-06-29 US US15/738,067 patent/US20180177734A1/en not_active Abandoned
- 2016-06-29 ES ES16739625T patent/ES2786549T3/es active Active
- 2016-06-29 PE PE2017002785A patent/PE20180411A1/es unknown
- 2016-06-29 JP JP2017566409A patent/JP6667556B2/ja active Active
-
2017
- 2017-12-17 IL IL256364A patent/IL256364A/en unknown
- 2017-12-21 CL CL2017003320A patent/CL2017003320A1/es unknown
- 2017-12-21 CO CONC2017/0013293A patent/CO2017013293A2/es unknown
- 2017-12-21 DO DO2017000306A patent/DOP2017000306A/es unknown
- 2017-12-21 EC ECIEPI201784331A patent/ECSP17084331A/es unknown
- 2017-12-21 SV SV2017005601A patent/SV2017005601A/es unknown
- 2017-12-22 PH PH12017502431A patent/PH12017502431A1/en unknown
-
2018
- 2018-06-27 HK HK18108248.3A patent/HK1248547A1/zh unknown
-
2019
- 2019-07-31 AU AU2019210558A patent/AU2019210558B2/en active Active
-
2020
- 2020-02-25 JP JP2020029330A patent/JP6978534B2/ja active Active
-
2021
- 2021-03-31 AU AU2021202009A patent/AU2021202009B2/en active Active
- 2021-09-01 JP JP2021142184A patent/JP2021185188A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017003320A1 (es) | Formulaciones farmacéuticas que contienen tenofovir y emtricitabina | |
| CY1122786T1 (el) | Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης | |
| CL2018001199A1 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
| MX2017016802A (es) | Formulaciones farmaceuticas. | |
| EP3256149A4 (en) | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | |
| CY1121999T1 (el) | Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης | |
| HUP1700253A1 (hu) | Szilárd orális gyógyszerkészítmények | |
| IL264880A (en) | Preparations for oral administration of active substances | |
| CY1122473T1 (el) | Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης | |
| MA55015A (fr) | Formulations pharmaceutiques | |
| AR108233A1 (es) | Composiciones farmacéuticas orales de nicotinamida | |
| GB2591396B (en) | Pharmaceutical suspension for oral dosage | |
| EA201991286A1 (ru) | Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин | |
| HUE062682T2 (hu) | Ibuprofén tartalmú orális gyógyszerészeti készítmény | |
| CR20170601A (es) | Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina | |
| JOP20170198A1 (ar) | صيغ صيدلية تشتمل على تينوفوفير و إيمترايسيتابين | |
| CY1123966T1 (el) | Διαδικασια για την παρασκευη νατριουχου εποπροστενολης ενισχυμενης σταθεροτητας | |
| ZA201804275B (en) | Oral pharmaceutical composition comprising taste-masked n-acetylcysteine | |
| CU20180036A7 (es) | Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana | |
| CY1119636T1 (el) | Φαρμακευτικο παρασκευασμα με βαση διοσμεκτιτη | |
| MA41643A (fr) | Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton | |
| EA201790387A1 (ru) | Фармацевтическая композиция для лечения острой зубной боли или боли в челюсти | |
| MX2013003022A (es) | Composiciones farmaceuticas de montelukast y levocetirizina. |